rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
15 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with gynecologic malignancy for whom treatment with carboplatin is indicated.
Age >/= 15 years.
Adequate hematologic, renal, and hepatic functions.
Life expectancy >/- 3 months. Karnofsky Performance Status >/= 80.
Signed informed consent form.
Patients with rapidly progressive disease.
Pregnant or lactating women.
Patients with comorbid condition which renders patients at high risk of treatment complication.
History of CNS metastasis.
Patients with significant cardiac disease (NYHA Class III or IV), dysrhythmia, or recent history of MI or ischemia, transient ischemic attack or CVA within the 6 months of study entry.
Prior chemotherapy, immunotherapy, any experimental drug within 4 weeks, use of myeloid (G-CSF or GM-CSF) growth factors within 2 weeks or erythropoietin within 4 weeks.
Use of any nitrosourea (BCNU, CCNU) or mitomycin - C within 6 weeks.
Prior surgery or RT within 2 wks of study entry.
Patients with history of prior high dose chemotherapy with stem cell transplant or with history of prolonged thrombocytopenia (> 2 weeks).
History of leukemia.
History of any platelet disorders including ITP, TTP or bleeding disorders.
History of > 3 prior chemotherapy regimens (all platinum regimens will be counted as 1 regimen).
Demonstrated lack of response to platinum-based therapy.